Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Your source for key insights into Cell and Gene-Based Therapy trends in development globally and the Indian market. 

    Understand the cell and gene therapy market with an expert look at  the trends and developments of cell and gene therapies globally, the types of agents under development, and examining the prospects for the Indian market specifically.

    Cell and gene therapies have been in development for over a quarter of a century now, but have experienced an explosion of interest in recent years.  With the introduction of Zolgensma, the entire concept of a single injection to cure a congenital disease that works like magic in saving lives, was finally proven as a way to deliver marketable therapeutics. As such, Gene therapy has become the most exciting field of Biotech research and continues to attract investors and big pharma as one of the most promising scientific frontiers. With the exciting new field of CAR-T therapies joining it, cell therapies incorporating ex vivo genetic manipulation have also joined the list of therapeutic options. 

    To understand this landscape and identify the potential new role for India’s pharma R&D, this exclusive and the first in a new series of webinars is being brought to you by IPA in collaboration with Informa Pharma Intelligence. 

Complete the form to register for our webinar!

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio
By ticking this box, you agree to receive emails such as promotional offers from other members of the Informa group and selected 3rd party companies


alt text

Ian Lloyd

Senior Director, Pharmaprojects & Data Integration
Informa Pharma Intelligence

Ian Lloyd is the Senior Director of Pharmaprojects and Data Integration, overseeing the content and analyst services for our drug development solution. He supports clients in their drug pipeline data requirements and drug pipeline inquiries, providing insight into the best search strategies to answer their drug research and development business questions.

alt text

Dr. Dhananjay Bakhle

Executive Vice President - Medical Research, Lupin Ltd 

Dr. Bakhle has been a veteran in the field of Pharmaceutical Medicine for the last 3 decades. He has covered all functions within pharmaceutical medicine and worked as Medical, Clinical & Regulatory Directors for several companies such as Schering-Plough, Novartis, Aventis & Sanofi and headed a full spectrum CRO of Reliance Industries. In his current role at Lupin, he heads the medical research group comprising of global clinical development, pharmacovigilance and Lupin Bioresearch Centre. He is based in Pune at the Lupin Research Park which is the state-of-the art Novel Drug Discovery & Development Centre of its kind in India.

Hosted and Moderated by:

alt text

Surdarshan Jain

Secretary General of Indian Pharmaceutical Alliance (IPA)

Sudarshan has a strong passion for healthcare and the education sector. Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (, Senior Advisor - Apax Partners and Board member of multiple organizations. He is the Chairman of the Indian Institute of Healthcare Management and Research (IIHMR, Jaipur). He has served in several leadership positions for over 40 years in the Healthcare industry (Lupin, Johnson & Johnson, Piramal, Abbott) and was formerly the Managing Director at Abbott Healthcare Solutions.

alt text

Anju Ghangurde

Scrip - Executive Editor, APAC

Anju is Executive Editor within the APAC team for Scrip and the Pink Sheet. She has over two decades of experience in journalism including stints at India's leading financial dailies. Based in Mumbai, India, she covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her.